This study aims to gain a deeper understanding of chronic lymphocytic leukemia (CLL) and common variable immunodeficiency (CVID) by studying immune cells and specific immune checkpoint signaling pathways. The analysis of the percentage of selected immune points and their ligands (PD-1/PD-L1, CTLA-4/CD86, and CD200R/CD200) on peripheral blood lymphocyte subpopulations was performed using flow cytometry, and additional analyses determining the serum concentration of the above-mentioned molecules were performed using enzyme immunoassay tests. The obtained results indicate several significant changes in the percentage of almost all tested molecules on selected subpopulations of T and B lymphocytes in both CVID and CLL patients in relation to healthy volunteers and between the disease subunits themselves. The results obtained were also supported by the analysis of the serum concentration of soluble molecules tested. By uncovering valuable insights, we hope to enhance our comprehension and management of these conditions, considering both immunodeficiencies and hematological malignancies. Understanding the role of these signaling pathways in disease development and progression may lead to the development of modern, personalized diagnostic and therapeutic strategies. Ultimately, this knowledge may enable the monitoring of the immune system in patients with CVID and CLL, paving the way for improved patient care in the future.
本研究旨在通过分析免疫细胞及特定免疫检查点信号通路，以深化对慢性淋巴细胞白血病（CLL）和普通变异型免疫缺陷病（CVID）的认识。我们采用流式细胞术检测了外周血淋巴细胞亚群中选定免疫检查点及其配体（PD-1/PD-L1、CTLA-4/CD86和CD200R/CD200）的表达百分比，并通过酶免疫分析法测定了上述分子的血清浓度。研究结果显示，与健康志愿者相比，CVID和CLL患者中几乎所有受检分子在特定T、B淋巴细胞亚群的表达比例均发生显著改变，且两种疾病亚组间也存在差异。可溶性分子血清浓度的分析结果进一步佐证了上述发现。通过揭示这些重要信息，我们希望从免疫缺陷和血液系统恶性肿瘤的双重视角，提升对这两种疾病的理解与管理水平。深入理解这些信号通路在疾病发生发展中的作用，或将推动现代个性化诊疗策略的发展。最终，这些认知可能实现对CVID和CLL患者免疫系统的动态监测，为未来改善患者诊疗路径奠定基础。
肿瘤(癌症)患者之家